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ABSTRACT
Identiﬁcation of subjects with a high risk of developing type 2 diabetes (T2D) is fundamental for
prevention of the disease. Consequently, it is essential to search for new biomarkers that can improve the
prediction of T2D. The aim of this study was to examine whether 5 DNA methylation loci in blood DNA
(ABCG1, PHOSPHO1, SOCS3, SREBF1, and TXNIP), recently reported to be associated with T2D, might predict
future T2D in subjects from the Botnia prospective study. We also tested if these CpG sites exhibit altered
DNA methylation in human pancreatic islets, liver, adipose tissue, and skeletal muscle from diabetic vs.
non-diabetic subjects. DNA methylation at the ABCG1 locus cg06500161 in blood DNA was associated
with an increased risk for future T2D (OR D 1.09, 95% CI D 1.02–1.16, P-value D 0.007, Q-value D 0.018),
while DNA methylation at the PHOSPHO1 locus cg02650017 in blood DNA was associated with a
decreased risk for future T2D (OR D 0.85, 95% CI D 0.75–0.95, P-value D 0.006, Q-value D 0.018) after
adjustment for age, gender, fasting glucose, and family relation. Furthermore, the level of DNA
methylation at the ABCG1 locus cg06500161 in blood DNA correlated positively with BMI, HbA1c, fasting
insulin, and triglyceride levels, and was increased in adipose tissue and blood from the diabetic twin
among monozygotic twin pairs discordant for T2D. DNA methylation at the PHOSPHO1 locus
cg02650017 in blood correlated positively with HDL levels, and was decreased in skeletal muscle from
diabetic vs. non-diabetic monozygotic twins. DNA methylation of cg18181703 (SOCS3), cg11024682
(SREBF1), and cg19693031 (TXNIP) was not associated with future T2D risk in subjects from the Botnia
prospective study.
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Introduction
Type 2 diabetes (T2D) is a complex disease that results from
genetic and environmental interactions that can be modiﬁed and/
or mediated by epigenetic changes.1-3 A number of genetic and
non-genetic factors have been identiﬁed that increase the risk of
T2D.4-9 However, a healthier lifestyle, including proper diet and
exercise, can potentially reduce the risk of T2D by almost 50
percent in high-risk groups.10,11 Therefore, there is great interest
and need to identify individuals that have a high risk of developing
T2D. By postponing and/or preventing T2D and its complications,
it may be possible to reduce T2D-associated mortality and the
ﬁnancial cost of treating the disease and its complications.
To date, more than 65 genetic variants have been identiﬁed
that increase the risk of T2D by almost 10 percent.6 However,
genetic screening for T2D risk variants has not been
implemented in the clinics. Despite the potential value of such
screening tests, a number of limitations have hindered their
use, including their small effect size, their low discriminative
ability, a small added value compared with the clinical risk fac-
tors, and a lack of models that take into account gene-gene and
gene-environment interactions.12 Thus, the search for new bio-
markers is ongoing. There is great interest in epigenetic bio-
markers such as DNA methylation, which, unlike the DNA
sequence, can be inﬂuenced by the environment, and hence
may potentially improve T2D prediction.
Recently, an epigenome-wide association study identiﬁed
5 DNA methylation loci (ABCG1, PHOSPHO1, SOCS3, SREBF1,
and TXNIP) in blood that were associated with future T2D. Fur-
thermore, the study showed that a methylation score that com-
bined the results from the 5 methylation loci was associated with
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future T2D incidence.8 The aim of this study was to replicate the
potential use of the 5DNAmethylation loci in bloodDNA recently
reported to be associated with T2D, in order to predict future T2D
in subjects from the Botnia prospective study. Furthermore, we
wanted to test if these loci and genes show altered DNA methyla-
tion and gene expression in primary target tissues for T2D from
diabetic vs. non-diabetic subjects.
Results
Prediction of T2D using DNA methylation loci
in blood DNA
For the prediction of T2D, we analyzed DNAmethylation of 5 CpG
sites: cg06500161 (ABCG1), cg02650017 (PHOSPHO1), cg18181703
(SOCS3), cg11024682 (SREBF1), and cg19693031 (TXNIP), which
have recently been reported to predict T2D,8 in blood DNA from
258 individuals from the Botnia prospective study whowere all non-
diabetic at baseline (Table 1). DNAmethylation at the ABCG1 locus
cg06500161 was associated with a 9% increased risk for future T2D
among people matched for age, gender, and fasting glucose levels
(OR D 1.09, 95% CI D 1.02–1.16, P-value D 0.007, Q-value D
0.018), while DNA methylation at the PHOSPHO1 locus
cg02650017 was associated with a 15% decreased risk for future T2D
among people matched for age, gender, and fasting glucose levels
(OR D 0.85, 95% CI D 0.75–0.95, P-value D 0.006, Q-value D
0.018). Furthermore, DNA methylation levels of both loci were still
associated with T2D risk after adjusting for leukocyte count:ABCG1
locus (OR D 1.10, P-valueD 0.004), and PHOSPHO1 locus (ORD
0.85, P-value D 0.007). None of the other 3 loci (SOCS3, SREBF1,
and TXNIP) were signiﬁcantly associated with the development of
T2D (Table 2). A methylation score combining the DNA methyla-
tion of the 5 CpG sites could not predict future T2D
(P-valueD 0.22).
Correlations between DNA methylation in blood DNA
and T2D risk factors
Next, for the 258 Botnia subjects who were non-diabetic at
baseline, we correlated DNA methylation at the 5 investi-
gated DNA methylation loci with risk factors for T2D, as
well as glucose and lipid phenotypes. DNA methylation at
the ABCG1 locus cg06500161 correlated positively with
BMI, HbA1c, fasting insulin, and triglyceride levels, while
Table 1. Clinical characteristics of study subjects from the Botnia prospective study at baseline and of monozygotic twin pairs discordant for T2D from whom blood sam-
ples and skeletal muscle biopsies were obtained.
Botnia prospective study MZ twins discordant MZ twins discordant
(Blood) for T2D (Blood) for T2D (Skeletal muscle)
Controls Converters Non-diabetic T2D Non-diabetic T2D
N (male/female) 129 (62/67) 129 (65/64) 19 (11/8) 17 (10/7)
Age (years) 51.4 § 9.1 52.8§ 12.3 66.5 § 8.0 66.8 § 7.3
BMI (kg/m2) 27.6 § 3.0 28.8§ 4.3 29.1 § 6.1 30.9§ 6.4 29.9 § 6.1 32.1 § 6.1
Fasting glucose (mmol/L) 5.1 § 0.4 5.3 § 0.6 6.2 § 0.6 9.7 § 3.0 6.1 § 0.6 9.9 § 2.5
Fasting insulin (pmol/L) 59.7 § 29.2 89.6§ 71.5 67.5 § 51.7 122.2 § 147.2 73.3 § 59.0 136.2 § 172.3
HbA1c
percent 5.5 § 0.5 5.7 § 0.5 5.9 § 0.4 7.4 § 1.7 5.8 § 0.4 7.6 § 1.7
mmol/mol 37.0 § 5.5 39.0§ 5.5 41.0 § 4.4 57.0§ 18.6 40.0 § 4.4 60.0 § 18.6
Cholesterol (mmol/L) 6.1 § 1.1 5.7 § 1.0 5.2 § 0.9 4.7 § 1.0 5.4 § 0.9 4.9 § 1.1
Triglycerides (mmol/L) 1.5 § 0.8 1.6 § 0.9 1.2 § 0.6 1.5 § 0.7 1.3 § 0.6 1.8 § 0.9
HDL cholesterol (mmol/L) 1.4 § 0.3 1.3 § 0.3 1.4 § 0.4 1.3 § 0.4 1.4 § 0.4 1.3 § 0.4
LDL cholesterol (mmol/L) — — 3.2 § 0.7 2.8 § 0.8 3.4 § 0.7 2.9 § 0.8
Have family history record 119 (91.5) 109 (88.6)
Leukocyte (£ 109/L) 6.0 § 1.5 6.7 § 1.9
Follow up (years) 9.3 § 3.5 6.9 § 3.5
Normal glucose tolerance 84 (64.6) 50 (38.7)
Data are presented as mean § SD or as number (%).P-value< 0.05, converters vs. controls and T2D vs. non-diabetic subjects.
Lipid and glucose phenotype data are based on 12 to 18 twin pairs.
LDL data is not available for the selected Botnia subjects at baseline.
Table 2. Associations between DNA methylation in CpG sites annotated to ABCG1, PHOSPHO1, SOCS3, SREBF1 and TXNIP and future T2D in subjects from the Botnia
prospective study.
DNA methylation (%)
CpG site Gene OR 95% CI P-value Q-value Controls Converters Delta N Gene region
cg06500161 ABCG1 1.09 1.02–1.16 0.007 0.018 65.9 § 4.2 67.2 § 5.7 1.3 216 Body
cg02650017 PHOSPHO1 0.85 0.75–0.95 0.006 0.018 2.7 § 2.2 1.9 § 2.1 ¡0.8 244 Body
cg18181703 SOCS3 0.97 0.93–1.02 0.22 0.275 52.4 § 6.2 51.3 § 6.0 ¡1.1 238 Body
cg11024682 SREBF1 0.99 0.95–1.03 0.68 0.680 49.4 § 6.4 49.7 § 6.4 0.2 239 Body
cg19693031 TXNIP 0.96 0.91–1.02 0.16 0.267 70.2 § 5.5 69.6 § 5.4 ¡0.6 247 30UTR
Logistic regression is corrected for age, gender, fasting glucose, and family relation.FDR was calculated for 5 tests.
Methylation data is presented as mean § SD. OR, odds ratio; CI, conﬁdence interval. UTR, untranslated region.
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DNA methylation at the PHOSPHO1 locus cg02650017 cor-
related positively with HDL levels (Table 3). Also, methyla-
tion at the SOCS3, SREBF1, and TXNIP loci correlated with
risk factors for T2D (Table 3).
Epigenetic dysregulation of DNA methylation in target
tissues for T2D
To test if DNA methylation of ABCG1, PHOSPHO1, SREBF1,
SOCS3, and TXNIP is dysregulated in primary target tissues for
T2D, we studied DNA methylation of all CpG sites annotated
to these 5 genes on the Inﬁnium 450K array in T2D case-con-
trol studies from human pancreatic islets and liver, and from
adipose tissue, skeletal muscle and blood obtained from mono-
zygotic twins discordant for T2D.13-17 Based on P < 0.05, we
found that DNA methylation of cg06500161 (ABCG1) was
increased in adipose tissue and blood from subjects with T2D,
DNA methylation of cg02650017 (PHOSPHO1) was decreased
in T2D skeletal muscle, DNA methylation of cg11024682
(SREBF1) was increased in T2D pancreatic islets, and DNA
methylation of cg19693031 (TXNIP) was decreased in pancre-
atic islets, skeletal muscle, and blood from subjects with T2D
(Table 4). In addition, a number of surrounding CpG sites in
these genes was also differentially methylated in human pan-
creatic islets, liver, adipose tissue, skeletal muscle, and blood
from diabetic vs. non-diabetic subjects (Supplementary
Table 2).
Correlations between DNA methylation and gene
expression in human tissues
We also wanted to investigate if the association between DNA
methylation and metabolic phenotypes/T2D potentially
could be mediated via altered expression of the nearest gene.
We correlated DNA methylation at the 5 studied CpG sites in
pancreatic islets, liver, adipose tissue, and skeletal muscle
with gene expression from the same tissue and subjects, using
available microarray data.13-17 We found that DNA methyla-
tion of cg18181703 correlated positively with SOCS3
expression in human pancreatic islets (Spearman’s rho D 0.19,
P-value D 0.033, Q-value D 0.16, n D 34), and negatively with
SOCS3 expression in adipose tissue (Regression coefﬁcient D
¡0.028, P-value D 0.002, Q-value D 0.011, n D 25). Addition-
ally, expression of ABCG1 and TXNIP was altered in muscle
from subjects with T2D, while expression of SREBF1 was
altered in both diabetic muscle and liver (Supplementary
Table 3). It should be noted that expression data from blood
was not available from subjects in the Botnia prospective study
or the T2D discordant twins.
Correlation between DNA methylation in blood with
methylation in adipose tissue and skeletal muscle
from the same subject
Finally, we investigated whether DNA methylation in blood
could be used as a surrogate marker for DNA methylation in
target tissues for T2D. DNA methylation at the 5 studied loci
Table 3. Correlations between DNA methylation and glucose and lipid phenotypes with P-value< 0.05 in blood from subjects from the Botnia prospective study.
CpG site Gene Pearson corr. P-value Q-value N Phenotype
cg06500161 ABCG1 0.21 0.001 0.008 224 BMI (kg/m2)
cg06500161 ABCG1 0.14 0.044 0.155 205 HbA1c (%)
cg06500161 ABCG1 0.23 0.001 0.006 218 Fasting Insulin (pmol/l)
cg06500161 ABCG1 0.22 0.001 0.006 209 Triglycerides (mmol/l)
cg02650017 PHOSPHO1 0.19 0.004 0.029 235 HDL (mmol/l)
cg18181703 SOCS3 ¡0.18 0.005 0.050 244 Age (years)
cg18181703 SOCS3 ¡0.13 0.041 0.125 245 BMI (kg/m2)
cg11024682 SREBF1 0.24 0.0002 0,006 246 Age (years)
cg11024682 SREBF1 0.15 0.022 0.099 247 BMI (kg/m2)
cg11024682 SREBF1 0.15 0.022 0.099 247 Fasting glucose (mmol/l)
cg11024682 SREBF1 0.13 0.050 0.155 228 HbA1c (%)
cg19693031 TXNIP ¡0.13 0.039 0.155 239 Triglycerides (mmol/l)
FDR was calculated for 40 tests.
Table 4. Differential DNA methylation of the 5 CpG sites annotated to ABCG1, PHOSPHO1, SOCS3, SREBF1 and TXNIP in T2D compared with non-diabetic subjects in
pancreatic islets, adipose tissue, skeletal muscle, and blood.
DNA methylation (%)
CpG Gene Non-diabetic T2D Delta P-value Q-value Tissue Ref.
cg06500161 ABCG1 56.7 § 2.3 57.9 § 2.8 1.2 0.032 0.135 Blood
cg06500161 ABCG1 43.9 § 5.3 47.7 § 5.2 3.8 0.025 0.123 Adipose tissue Nilsson et al.
cg02650017 PHOSPHO1 26.3 § 5.7 24.2 § 5.4 ¡2.1 0.020 0.123 Skeletal muscle
cg11024682 SREBF1 52.0 § 5.8 59.5 § 8.4 7.5 0.045 0.160 Pancreatic islets Dayeh et al.
cg19693031 TXNIP 63.4 § 4.3 59.4 § 6.6 ¡4.0 0.020 0.123 Skeletal muscle
cg19693031 TXNIP 67.6 § 4.5 64.7 § 6.5 ¡3.0 0.023 0.123 Blood
cg19693031 TXNIP 56.7 § 10.4 44.8 § 10.4 ¡11.9 0.0006 0.016 Pancreatic islets Dayeh et al.
FDR was calculated for 25 tests.
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in blood was correlated with DNA methylation of the corre-
sponding CpG site in adipose tissue and skeletal muscle
obtained from the same subject. We found that DNA methyla-
tion of cg18181703 (SOCS3) and cg11024682 (SREBF1) in
blood correlated with the degree of methylation in adipose tis-
sue (Regression coefﬁcient D 0.31 and 0.40, P-value D 0.010
and 0.052, n D 28).
Discussion
In this study, we replicated the recently reported association
between DNA methylation at cg06500161 (ABCG1) and
future T2D in subjects from the Botnia prospective study. Fur-
thermore, DNA methylation at cg06500161 in blood correlated
positively with BMI, HbA1c, fasting insulin, and triglyceride
levels, and it was increased in adipose tissue and blood from
the diabetic twin among monozygotic twin pairs discordant for
T2D.
ABCG1 encodes a member of the ATP-binding cassette
(ABC) protein family, which plays a role in the homeostasis of
glucose and lipids. These proteins do so by removing excess
cholesterol from peripheral tissues and transporting it to the
liver.18 The HDL-mediated increase in insulin secretion is
dependent on ABCG1. Loss of both ABCA1 and ABCG1 results
in sterol accumulation, impaired glucose-stimulated insulin
secretion, and inﬂammation of pancreatic b-cells.19
Recently, DNA methylation at cg06500161 (ABCG1) in
blood was associated negatively with HDL-C levels and posi-
tively with triglyceride levels and myocardial infarction. In
addition, methylation of 2 CpG sites in ABCG1 in adipose tis-
sue was also positively associated with triglyceride levels.7
Another study showed that DNA methylation of cg06500161
in CD4C T cells was associated positively with fasting insulin
levels and HOMA-IR.20 Importantly, our ABCG1 methylation
data are in line with these studies.
DNA methylation at cg06500161 in blood has been shown
to correlate negatively with ABCG1 expression in blood.7,8
These authors showed that the strength of the association var-
ied for the 6 different ABCG1 transcripts. Furthermore, an elec-
trophoretic mobility shift assay (EMSA) showed that
methylated cg06500161 had a lower binding afﬁnity to an
unknown protein complex compared with unmethylated
cg06500161.7 A recent study showed that the relationship
between BMI and expression of ABCG1 in monocytes is par-
tially mediated through DNA methylation.21 Interestingly,
ABCG1 has shown allelic imbalance of expression in human
pancreatic islets, and in lymphoblastoid cell lines, suggesting
that altered allelic expression of ABCG1 may result from both
genetic and epigenetic mechanisms.22,23 Accordingly, we found
that ABCG1 expression was reduced in skeletal muscle from
subjects with T2D. Taken together, these ﬁndings point toward
the importance of taking into consideration the different
ABCG1 transcripts that might be expressed in different tissues
and genetic variation.
Genetic variation in coding SNPs in ABCG1 has not previ-
ously been associated with increased risk of T2D.24 However, a
recent study integrated regional ABCG1 SNP data with methyl-
ation of cg06500161 and identiﬁed a number of methylation
quantitative trait loci (cis-meQTLs), some of which were asso-
ciated with insulin and HOMA-IR.20 It will be interesting to
examine whether combining genetic, clinical, and epigenetic
information provides us with better prediction models for
diabetes.
PHOSPHO1 encodes a phosphatase that is highly expressed
in skeletal muscle and plays a role in skeletal mineralization.
Under certain circumstances, it may also cause vascular miner-
alization.25-27 Cardiovascular calciﬁcation is a common conse-
quence of aging, diabetes, and hypercholesterolemia.28
PHOSPHO1, is considered to be an attractive target for cardio-
vascular therapy.26 Interestingly, we found that DNA methyla-
tion at the PHOSPHO1 locus cg02650017 in blood correlated
positively with HDL levels. Furthermore, DNA methylation at
the PHOSPHO1 locus cg02650017 was decreased in skeletal
muscle from diabetic vs. non-diabetic monozygotic twins, while
its expression was not altered.
Epigenetic alterations have been reported for numerous
genes in pancreatic islets, liver, adipose tissue, and skeletal
muscle from subjects with T2D compared with non-diabetic
controls.13-15,17 However, the potential use of T2D-associ-
ated DNA methylation patterns in target tissues for disease
prediction is hindered by the inaccessibility of these tissues,
and will only become feasible if we could ﬁnd biomarkers
in easily accessible tissues that reﬂect the changes in inter-
nal and inaccessible tissues. In this study, we found that
DNA methylation of cg06500161 (ABCG1) was increased in
adipose tissue and blood from the same individual and that
DNA methylation of cg19693031 (TXNIP) was decreased in
pancreatic islets, skeletal muscle, and blood from subjects
with T2D compared to controls. Furthermore, DNA meth-
ylation at cg18181703 (SOCS3) and cg11024682 (SREBF1)
in blood correlated with DNA methylation levels in adipose
tissue from the same individual. Recently, we have shown
that age-associated DNA methylation changes in blood mir-
ror DNA methylation changes in human adipose tissue
from elderly compared with young subjects.29 We found
that methylation of a number of CpG sites in and sur-
rounding the 5 investigated loci was altered in pancreatic
islets, adipose tissue, skeletal muscle, and blood from sub-
jects with T2D compared with non-diabetic controls. These
epigenetic dysregulations at the same loci, but in different
tissues from the same individual, may be mediated by so-
called ‘metastable epialleles’; that is, “alleles that are variably
expressed in genetically identical individuals due to epige-
netic modiﬁcations that are established during early devel-
opment”.30 Despite the stochastic nature of these epigenetic
modiﬁcations, they might be inherited transgenerationally,
altered by the environment, and can affect all tissues of the
body.30
The use of DNA methylation biomarkers in the clinic is still
limited, and has been hindered by insufﬁcient sensitivity and
speciﬁcity. However, there are a number of advantages of using
DNA methylation as a biomarker. For example, DNA methyla-
tion is quite stable over time, since it is covalently attached to
the DNA. In addition, the degree of DNA methylation is inde-
pendent of the amount of starting material, since most methods
used for DNA methylation analysis determine the ratio of
methylated to unmethylated CpG sites.31
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Our inability to replicate 3 of the associations reported
by Chambers et al. 8 could be explained by our modest
sample size and differences in study design. Performing a
power calculation revealed that we would need a larger
sample size to be able to detect the effect size reported by
Chambers et al. In addition, a larger sample size would be
needed to compare the speciﬁcity and sensitivity of the
identiﬁed DNA methylation biomarkers in blood in com-
parison to clinical and genetic screening.
Conclusion
In this study, we have shown that DNA methylation at 2 CpG
sites in ABCG1 and PHOSPHO1 are associated with future
T2D risk in the Botnia prospective cohort. Furthermore, in
healthy subjects, DNA methylation at both loci in blood DNA
was associated with a number of T2D risk factors, such as BMI,
HbA1c, fasting insulin levels, triglycerides, and HDL levels.
Interestingly, we found that the altered DNA methylation
observed in blood was also found in human target tissues for
T2D: pancreatic islets, liver, adipose tissue, and skeletal muscle.
Our data suggest that DNA methylation biomarkers in blood
might be used as surrogate markers for DNA methylation in
inaccessible target tissues. More importantly, the occurrence of
altered DNA methylation in more than one human tissue at
the same locus could be mediated by so-called ‘metastable epi-
alleles’. The search for T2D-associated DNA methylation bio-
markers is still in its infancy. The few studies conducted to date
have screened less than 2 percent of CpG sites in the human
genome and it is possible that many more DNA methylation
biomarkers will be identiﬁed in the coming years. The hope is
that they perform better than existing biomarkers.
Materials and methods
Study subjects
Botnia prospective study
For the prediction of T2D, we selected samples from the Botnia
prospective study. This family-based study includes 2,770
participants from the Botnia region in Finland, who were all
non-diabetic at baseline. Participants were followed prospec-
tively, using repeated oral glucose tolerance tests (OGTTs) to
detect progression toward T2D. The cohort has been previously
described.32 DNA was extracted from whole blood taken at
baseline. In this study, we used DNA from 129 participants
who developed T2D (converters) over a mean follow-up time
of 8.1 § 3.7 years, and 129 participants who did not develop
T2D (controls) over the same follow-up time. The controls
were matched with converters for age and gender at baseline.
Clinical characteristics of study subjects are shown in Table 1.
At baseline, the converters had signiﬁcantly higher BMI, fasting
glucose levels, fasting insulin levels, HbA1c levels, leukocyte
counts, and lower cholesterol and HDL levels compared with
controls.
Monozygotic twin pairs discordant for T2D
Adipose tissue (14 pairs), skeletal muscle (17 pairs), and blood
cells (19 pairs) from monozygotic twins discordant for T2D
were used in this study. Adipose tissue, skeletal muscle, and
blood from the same individual were available for 9 of the twin
pairs. Clinical characteristics for the 14 twin pairs from whom
adipose tissue was obtained have been previously described,13
and skeletal muscle from some of the twins have been investi-
gated in several studies.15,16,33 Clinical characteristics of the
twin pairs from whom skeletal muscle and blood were obtained
are shown in Table 1. Diabetic twins had signiﬁcantly higher
BMI, fasting glucose levels, and HbA1c levels compared with
non-diabetic twins.
Human pancreatic islets
In this study, we used human pancreatic islets from 15 T2D
and 34 non-diabetic donors. The clinical characteristics for
these donors have been previously described.14 T2D donors
had higher HbA1c levels and lower levels of glucose-stimulated
insulin secretion.
Human liver
In this study, we used human liver DNA methylation data from
participants of the Kuopio Obesity Surgery Study (KOBS)—35
with T2D and 60 without. The clinical characteristics for these
subjects have been previously described.17 As expected, subjects
with T2D had signiﬁcantly higher fasting plasma glucose levels
and fasting insulin levels than non-diabetic subjects.
DNA methylation analysis
Pyrosequencing was used to analyze DNA methylation of 5 dif-
ferent CpG sites in ABCG1, PHOSPHO1, SOCS3, SREBF1, and
TXNIP in blood DNA from the Botnia subjects as previously
described.14 Primer sequences used for pyrosequencing are
included in Supplementary Table 1. Genome-wide DNA meth-
ylation analysis of human pancreatic islets, liver and from adi-
pose tissue, skeletal muscle and blood from monozygotic twins
discordant for T2D was performed using the Inﬁnium Human-
Methylation450 BeadChips (Illumina), according to the manu-
facturer’s instructions. The genome-wide DNA methylation
data from human pancreatic islets, liver, adipose tissue, and
skeletal muscle from some of the subjects has been previously
published.13,14,16,17
Gene expression analysis
mRNA expression data of the human pancreatic islets, adipose
tissue and skeletal muscle were analyzed using the GeneChip
Human Gene 1.0 ST array from Affymetrix (Santa Clara, CA,
USA) according to the manufacturer’s recommendations.
mRNA expression from liver from a subset of subjects (19 T2D
and 23 non-diabetic subjects) was analyzed using the
HumanHT-12 Expression BeadChip from Illumina according
to the manufacturer’s recommendations. mRNA expression
data from pancreatic islets, liver, and adipose tissue have previ-
ously been published.13,14,17
Statistics
To test if DNA methylation of the 5 analyzed CpG sites in
ABCG1, PHOSPHO1, SOCS3, SREBF1, and TXNIP was
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associated with future T2D in subjects from the Botnia pro-
spective study we performed logistic regression analysis for
each CpG site using a robust variance estimator in order to
take care of possible dependency within families using STATA
(StataCorp). Covariates included in the logistic regression
model were age, sex, and fasting glucose at baseline. For each
participant, standardized values of each “methylation level”
(expressed in SD units from the mean) were summed to pro-
duce the methylation score; methylation score D ZTXNIP C
ZSREBF1 C ZSOCS3 C ZPHOSPHO1 C ZABCG1, where
ZTXNIP D (TXNIP-mean (TXNIP))/SD (TXNIP) and so on.
For the Botnia cohort, we used Pearson correlations to deter-
mine whether DNA methylation at the 5 CpG sites in blood
was correlated to T2D risk factors, and glucose and lipid phe-
notypes. For discordant twins, we used regression analysis to
correlate expression and methylation, taking twin pair relation-
ship into account. We also used regression analysis to correlate
DNA methylation between tissues from the same individual.
We used a paired Wilcoxon test to compare DNA methylation
and gene expression between monozygotic twins discordant for
T2D. We used a false discovery rate (FDR) analysis to correct
for multiple testing.
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